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Background: Cholera, an infectious disease caused by Vibrio cholerae, is a major public health problem and is a
particularly burden in developing countries including Nepal. Although the recent worldwide outbreaks of cholera
have been due to V. cholerae El Tor, the classical biotypes are still predominant in Nepal. Serogroup O1 of the V. cholerae
classical biotype was the primary cause of a cholera outbreak in Kathmandu in 2012. Thus, this study was
designed to know serotypes and biotypes of V. cholerae strains causing recent outbreak with reference to drug
resistant patterns. Moreover, we also report the toxigenic strains of V. cholerae from both environmental and
clinical specimens by detecting the ctx gene.
Methods: Twenty four V. cholerae (n = 22 from stool samples and n = 2 from water samples) isolated in this
study were subjected to Serotyping and biotyping following the standard protocols as described previously. All
of the isolates were tested for antimicrobial susceptibility patterns using the modified Kirby-Bauer disk diffusion
method as recommended by CLSI guidelines. The screening of the ctx genes (ctxA2-B gene) were performed by
PCR method using a pair of primers; C2F (5′-AGGTGTAAAATTCCTTGACGA-3′) and C2R (5′-TCCTCAGGGTATCCTTCATC-3′)
to identify the toxigenic strains of V. cholerae.
Results: Among twenty four V. cholerae isolates, 91.7% were clinical and 8.3% were from water samples. Higher rate of
V. cholerae infection was found among adults of aged group 20–30 years. All isolates were serogroups O1 of the V. cholerae
classical biotype and sub serotype, Ogawa. All isolates were resistant to ampicillin, nalidixic acid and cotrimoxazole. 90.9%
were resistant to erythromycin however, tetracycline was found to be the most effective drug for the isolates. All isolates
were multidrug resistant (MDR) and possessed a ctx gene of approximately 400 base pairs indicating the toxigenic strains.
Conclusion: Hundred percent strains of V. cholerae were MDR possessing a ctx gene. It suggests that toxigenic strains be
identified and proper antibiotic susceptibility testing be conducted. This will allow effective empirical therapy to be used to
treat and control cholera.
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Cholera is the second leading cause of mortality world-
wide among children under 5 years, and is one of the
main causes of morbidity in adults [1,2]. The causative
agent of cholera, Vibrio cholerae is a genetically versatile
bacterial species [3]. More than two hundred serogroups
were identified on the basis of the somatic O antigens* Correspondence: upendrats@gmail.com
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article, unless otherwise stated.[4] among which O1 and O139 are two major virulent
strains. Two biotypes of V. cholerae O1; classical and El
Tor are the causative agents of the sixth and the seventh
pandemics respectively [5]. Organisms of both biotypes
of serogroup V. cholerae O1 are further subdivided into
Serotypes; Inaba, Ogawa and Hikojima [6]. V. cholerae
O1 is still frequently isolated from many outbreak re-
gions of Asian countries [7]. Nepal is still a cholera en-
demic country where cholera outbreaks occur every year
in the major cities including Kathmandu Valley causing
significant morbidity and mortality [8-10].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sociated with the CTX genetic element which corre-
sponds to CTX Φ (prophage), a lysogenic filamentous
bacteriophage. The genetic element comprises of two
gene clusters, the core and the RS2 regions. The core re-
gion contains ctx genes encoding the cholera toxin (CT)
and five more genes encoding the required components
for phage morphogenesis [7]. The toxin produced is
transported extracellularly by type II secretion system
disrupting the ion transport of intestinal epithelial cells
[11]. The subsequent loss of water and electrolytes leads
to severe secretory diarrhoea, a characteristic of cholera
[12]. The presence of such genes confirms the toxigenic
strains of V. cholerae.
The poor socio-economic status, inadequate sanitation
and poor access to safe drinking water are the major pre-
disposing factors of cholera outbreaks in many cities of
Nepal. V. cholerae usually spreads by the faecal-oral route
by ingesting faecally contaminated water or food, person to
person transmission and direct contact with infected faeces
as described in previous studies. Antimicrobial therapy is
commonly recommended for shortening the duration or
reducing the severity of symptoms as well as lessening
bacterial excretion. However the problem of antimicrobial
resistance among the agent continues to be alarming. Des-
pite few studies on diarrhoeal diseases in Nepal, there is
lack of adequate information on bacterial enteric pathogens
and their antimicrobial resistance trend has been changed
over a longer time period globally and in Kathmandu valley
as well [9,13,14]. In addition, emergence of multidrug re-
sistant V. cholerae isolates is a major problem in developing
countries today [15]. Since most diarrhoeal diseases are
treated empirically, it is important to know the susceptibil-
ity pattern of the prevalent pathogens. Hence, this study
aimed to identify the toxigenic strains of V. cholerae isolates
from clinical and environmental samples in Kathmandu
city and to know their changing resistant profiles.
Methods
Informed consent and ethical approval
Written consent was obtained from the participants’
involved in the research study. The research ethics was
approved by Nepal Health Research Council (NHRC),
Kathmandu, Nepal.
Isolation, identification and typing of V. cholerae
During cholera outbreak in Kathmandu city in 2012, a
total of 450 stool samples from patients with diarrhoea
and 30 drinking water samples from the cholera outbreak
regions in the Kathmandu city were collected. The sam-
ples were enriched in alkaline peptone water (pH-8.4) at
37°C for 4–6 hours, followed by overnight culture on
selective media; thiosulphate citrate bile sucrose agar
(TCBS-HiMedia). The sucrose fermenting yellow colonieswere subjected to biochemical tests [16] and Serotyping
using kit (Mast Group and Denka Seiken, Japan) as per
the kit’s instructions. The biotyping of the strains were
assayed using the Polymyxin B (50 U) sensitivity test,
Voges Proskauer reaction in methyl red Voges Proskauer
(MRVP-HiMedia) broth medium and chicken RBC agglu-
tination tests [6].
Antibiotic susceptibility test
The antimicrobial susceptibility testing of the isolates to
various antimicrobial disks (HiMedia: Ampicillin-10mcg,
Nalidixic acid-30mcg, Ciprofloxacin-5mcg, Cotrimoxa-
zole1.25/23.75mcg, Cefotaxime-30mcg, Chloramphenicol-
30mcg, Tetracycline-30mcg and Erythromcycin-15mcg) was
performed using the modified Kirby-Bauer disk diffusion
method as recommended by Clinical and Laboratory
Standards Institute guidelines [17]. Escherichia coli (ATCC,
25922) was used for the standardization of the Kirby-Bauer
test for correct interpretation of the zone diameters.
Molecular assay
PCR assay was selected as a molecular assay in this
study. The genomic DNA of all isolates were extracted
and purified from the aerobically grown culture in Luria
Bertani (LB) broth and used for the specific PCR for the
detection of ctx genes [18]. A pair of primers (Macrogen,
Republic of Korea); C2F (5′-AGGTGTAAAATTCCTT
GACGA-3′) and C2R (5′-TCCTCAGGGTATCCTTCA
TC-3′) were used for the gene amplifications as de-
scribed by Patrick et al. [19]. The reaction mixture for
the gene amplification was prepared in 25 μl consisting
of 12.5 μl QIAGEN multiplex PCR master mix, 1 μl
10 μM forward primer, 1 μl 10 μM reverse primer, 9.5 μl
distilled water and 1.0 μl of template DNA. The amplifica-
tions were performed as follows: an initial pre-denaturation
at 94°C for 15 minutes followed by 35 cycles at 94°C for
30 seconds (denaturation), 60°C for 60 seconds (primer an-
nealing), 72°C for 60 seconds (DNA extension) and a final
elongation was performed at 72°C for 10 minutes on a ther-
mocycler (Thermal cycler Perkin Elmer cetus P11966). The
amplified products were fractionated by electrophoresis
through 1.5% agarose gel with NEB 100 bp marker DNA
which was visualized by staining the gel with ethidium
bromide [19].
Data analysis
Data were entered and analyzed using SPSS software for
Windows (version 16). Chi square test was used as a
statistical tool to correlate between different age groups
and V. cholerae infection rate.
Results
Altogether twenty four V. cholerae were isolated of
which 91.7% (n = 22) were from patients with diarrhoea
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Among the clinical isolates, 50% were isolated from adult
patients of aged 20–30 years. There was significant differ-
ence in V. cholerae infection rate among 20–30 years aged
patients as compared to other age groups (p = 0.018).
Serotyping and biotyping of V. cholerae
All strains were found to be serogroup O1, serotype
Ogawa and the Classical biotypes (Table 1).
Antibiotic resistance patterns
All clinical V. cholerae strains were susceptible to tetracyc-
line. However, 90.9% was susceptibility to both ciprofloxa-
cin and chloramphenicol. The sensitivity to cefotaxime
was 81.8%. All isolates were found to be resistance to
ampicillin, nalidixic acid and cotrimoxazole and 90.9% iso-
lates were resistance to erythromycin.
Among the environmental V. cholerae isolates, all were
resistance to ampicillin, nalidixic acid, cotrimoxazole and
erythromycin. Fifty percent (n = 1) isolates were resistance
to chloramphenicol as well (Table 2).
Antibiotic resistance profiles
Five different types of resistant profiles were observed
among the clinical isolates which were named as the
clinical resistant type 1 to type 5 profiles. Two isolates
were resistance to only three antibiotics; ampicillin, nali-
dixic acid, cotrimoxazole named as clinical resistant type
1 (CR1) profile. Higher no. of isolates; 68.2% (n = 15)
were of the CR2 type. Similarly, the resistant types, CR3,
CR4 and CR5 were seen in 13.6%, 4.5% and 4.5% isolates
respectively (Table 3).
Similarly two different resistant types were observed
among V. cholerae isolates from environmental specimen.
Fifty percent (n = 1) was of the environmental resistant type
1 (ER1) profile which was found to resist antibiotics such as
ampicillin, nalidixic acid, cotrimoxazole and erythromycin.
The remaining 50% showed an ER2 type (Table 3).
Multidrug resistant V. cholerae and detection of ctx gene
All of the isolates were found to be multidrug resistant
(Table 2) and highly pathogenic strains possessing the
ctx gene of approximately 400 base pairs (Figures 1 and 2).Table 1 Serotyping and Biotyping of V. cholerae
Typing methods Tests performed Seroty
Serotyping Agglutination (Mast Group







Cholera is one of the most predominant diarrhoeal dis-
eases in Nepal even these days. In this study, we found
evidence of V. cholerae in 4.9% of cholera cases among
patients with diarrhoea and in 6.67% of drinking water
samples. A study by Karki and Tiwari in Kathmandu
reported 25.1% cholera cases in 2004 [20] and study by
Tamang et al. in Kavre reported 31% of positive cases
for V. cholerae in the same year [21]. The frequencies
of V. cholerae among patients with diarrhoea were
found to be still higher in the studies carried out by
Kansakar et al. (11.17%), Karki et al. (27.1%) and Shah
et al. (8.21%) [22-24]. The higher rate of the pathogens
in the previous studies might be due to the hospital
based analysis, however the prevalence may be lower
among community based studies. The diarrhoeal cases
were not only due to V. cholerae in our study. This study
also reported 4% of diarrhoea caused by Shigella spp
(Shigella flexneri; n = 14 and Shigella sonnei; n = 4) and
1.33% was due to intestinal parasites (Entamoeba histolytica;
n = 3, Cyclospora cayetanesis; n = 2 and Blasocystis hominis;
n = 1). The detail of results was not shown here. The predis-
posing factors such as poor sanitation, lack of safe drinking
water and unhygienic foods preparations were found to be
responsible for the repeated occurrence of the pathogens in
Kathmandu and other districts of Nepal.
Vibrio cholerae El Tor O1 Ogawa was responsible for
the endemics in Nepal before 2012 [21,24] and previous
outbreaks of cholera in Kathmandu valley in 2004 [25]. In
contrast, all of the isolates in this study were the V. cholerae
O1 serogroups Ogawa and the classical biotype. Infections
with classical strains are generally more severe than
those with El Tor strains [6]. Three strains; V. cholerae
O1 biotype El Tor, V. cholerae O1 biotype Classical
and V. cholerae O139 have been frequently isolated in
cholera outbreaks in Asian countries [26]. Although
classical V. cholerae O1 caused the fifth and sixth pan-
demics, and presumably the earlier pandemics, the sev-
enth pandemic was attributed to the El Tor biotype,
which has been replaced by the classical biotype in this
study. The Inaba and Hikojima sero subtypes were not
found in this study. Other research conducted in Nepal
had reported the occurrence of both Ogawa and Inaba
serotypes with an interval of several years [21,27-29].pes No of positive strains (%) Types






Table 2 General antibiotic susceptibility pattern of V. cholerae (total no = 24)
Antibiotics
used (HiMedia)
Clinical isolates (n = 22) Environmental isolates (n = 2)
No. of Resistant (%) No. of Sensitive (%) No. of Resistant (%) No. of Sensitive (%)
Ampicillin 22 (100) 0 2 (100) 0
Nalidixic acid 22 (100) 0 2 (100) 0
Ciprofloxacin 2 (9.1) 20 (90.9) 0 2 (100)
Cotrimoxazole 22 (100) 0 (81.8) 2 (100) 0
Cefotaxime 4 (18.2) 18 0 2 (100)
Chloramphenicol 2 (9.1) 20 (90.9) 1 (50) 1 (50)
Tetracycline 0 22 (100) 0 2 (100)
Erythromcycin 20 (90.9) 2 (9.1) 2 (100) 0
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cholera [2,30,31]. Contrary to this, adult populations of
age group 20–30 years were highly infected accounting
for 8.7% as compared to all other aged groups (3.4%)
in our context (p = 0.018). The studies by Kansakar
et al. [22] and Yadav et al. [32] found similar results in
which most of the infected patients were adults aged
20 to 29 years and 15 to 29 years respectively. The
greater incidence of infections in these groups was
found because of their food habits outside the home
including consumption of street food.
All the strains in this study were resistant to nalidixic
acid, cotrimoxazole and ampicillin suggesting these drugs
should not be used in the treatment of cholera. Das et al.
also reported 100% resistance to the above three antibi-
otics [33]. A high incidence of cotrimoxazole resistant
V. cholerae O1 strains has been reported in the studiesTable 3 Antibiotic resistant profile of V. cholerae isolates
Resistant
types
Resistant profiles No. of isolates (%)
Clinical isolates
CR1 Ampicillin, Nalidixic acid, Cotrimoxazole 2 (9.1)
CR2 Ampicillin, Nalidixic acid, Cotrimoxazole,
Erythromycin
15 (68.2)
CR3 Ampicillin, Nalidixic acid, Cotrimoxazole,
Erythromycin, Cefotaxime
3 (13.6)









ER1 Ampicillin, Nalidixic acid, Cotrimoxazole,
Erythromycin
1 (50)
ER2 Ampicillin, Nalidixic acid, Cotrimoxazole,
Erythromycin, Chloramphenicol
1 (50)
Note: CR-Clinical resistant type, ER- Environmental resistant type.in Africa, Asia and South America [34,35]. The study
by Karki and Tiwari [20] found that all the V. cholerae
strains were resistance to ampicillin while 97.8% isolates
were susceptible to ciprofloxacin. Generally, fluoroquino-
lones have excellent activity against cholera [20] however;
fluoroquinolone resistant strains of V. cholerae have
recently been reported from India [33,36,37]. The ma-
jority of V. cholerae strains in our study were susceptible
to tetracycline (100%), ciprofloxacin (90.9%), cefotaxime
(81.8%) and chloramphenicol (90.9%) which may be effect-
ive alternative drugs for the treatment of cholera. However
the development of resistance needs to be monitored. A
similar result was also found by Shah et al. [24] showingFigure 1 Amplification of ctx gene in V. cholerae isolates (L-Ladder,
PC-Positive control, NC-Negative control, clinical V. cholerae isolate;
210, 130, 262, 457 202, 274, 219, 306, 126, 256, 201, 248, 232, 297,
349, 222, 303, 335, 283, 117, 253 showing positive ctx band).
Figure 2 Amplification of ctx gene in V. cholerae isolates (L-Ladder, PC-Positive control, NC-Negative control, clinical V. cholerae isolate;
130, 208 and environmental isolates; E9 E23 showing positive ctx band).
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phenicol respectively. However they showed that 81.8% of
strains were resistant to tetracycline. Garg et al., reported
high-level resistance to chloramphenicol in India. This re-
sult contrasted to our findings [13]. Macrolide resistance
was rarely reported in the studies by Harris et al., 2012
and Kanskar et al., 2011 [2,22], yet a high level erythro-
mycin resistance (90.9%) was found in our study. Resist-
ance to erythromycin and other antimicrobial agents
among V. cholerae can be acquired through selected mu-
tations over the time, or due to widespread use of antibi-
otics for prophylaxis in asymptomatic individuals [38].
All V. cholerae were found to be multidrug resistance
in the study. MDR cholera epidemics have been reported
from Bangladesh [39], Pakistan [40] and Nepal [9,23].
Indiscriminate use of antibiotics in the treatment of
cholera and other enteric diseases has led to the emer-
gence of antibiotic resistance among V. cholerae. Epidemics
of MDR cholera (both classical and El Tor biotypes) have
been reported worldwide [41]. MDR in V. cholerae can be
attributed to either a spontaneous mutation or to the hori-
zontal transfer of resistance genes between members of gut
coliform or other co-existing microflora and Vibrio spp
[42].
All V. cholerae strains tested in our study possessed
the ctx gene. Toxigenic strains of V. cholerae contained
the essential genetic element, CTX [43,44]. The isolates
in the study were thus confirmed as toxigenic strains.
The ctx genes are located in the CTX element and en-
code the cholera toxin CT. This toxin is primarily re-
sponsible for the severe secretory diarrhoea in infected
person. Thus we screened all the isolates for the pres-
ence of ctx gene. Our results showed the presence of ctx
gene of approximately 400 bp (~385 bp) in all the testedstrains similar as described by Patrick et al. [19]. Similar
genes were also detected in the environmental isolates.
Chakraborty et al. [45] also found the critical virulence
genes in the environmental strains of V. cholerae.
Conclusions
V. cholerae is one of the major agents associated with
diarrhoea outbreaks in Nepal with highest propensity
during the rainy seasons. The burden of diarrhoea de-
pends upon the strain and not all V. cholerae are toxi-
genic and epidemic. So, it is suggested that V. cholerae
regularly be examined for the presence of the ctx gene
from clinical and non-clinical samples to ensure identifi-
cation of the toxigenic strain. Proper antibiotic suscepti-
bility testing of V. cholerae is important to guide
appropriate antimicrobial therapy.
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